UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 30, 2009
ONCOGENEX PHARMACEUTICALS,
INC.
(Exact name of registrant as
specified in its charter)
| Delaware | 033-80623 | 95-4343413 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 1522 217th Place
S.E. Bothell, Washington |
98021 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (425) 686-1500
| N/A |
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01
Regulation FD Disclosure.
On May 30, 2009,
OncoGenex Pharmaceuticals, Inc. issued two press releases entitled
“OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival
Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate
Cancer” and “OncoGenex Pharmaceuticals Announces OGX-427 Treatment
Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and
Reductions in Tumor Markers in a Phase 1 Cancer Trial.” A copy of the
press releases are attached as Exhibit 99.1 and 99.2, respectively, and
incorporated herein by reference.
In accordance with General
Instruction B.2 of Form 8-K, the information in this report, including the
exhibit attached hereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), nor shall such information be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
Description | |
|
|
||
|
99.1
|
Press release of OncoGenex Pharmaceuticals, Inc. dated May 30, 2009 | |
|
99.2
|
Press release of OncoGenex Pharmaceuticals, Inc. dated May 30, 2009 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ONCOGENEX PHARMACEUTICALS, INC.
Date: June 2, 2009
/s/ Stephen Anderson
Stephen Anderson
Chief Financial Officer and Secretary
EXHIBIT INDEX
| Exhibit No. | Description | |
|
99.1
|
Press release of OncoGenex Pharmaceuticals, Inc. dated May 30, 2009 | |
|
99.2
|
Press release of OncoGenex Pharmaceuticals, Inc. dated May 30, 2009 |